A standard review process has been initiated for AstraZeneca and Oxford University’s coronavirus vaccine, AZD1222, driving to the voluntary suspension of vaccination across every trial. This will enable the independent committee to assess the safety data of a single incident of an unidentified disease that occurred in the phase III trial in the UK.
“A standard review process has been initiated for AstraZeneca and Oxford University’s coronavirus vaccine.“
Chief Executive Officer, Pascal Soriot, stated: "At AstraZeneca, we put science, safety and the interests of society at the heart of our work. This temporary pause is living proof that we follow those principles while a single event at one of our trial sites is assessed by a committee of independent experts. We will be guided by this committee as to when the trials could restart so that we can continue our work at the earliest opportunity to provide this vaccine broadly, equitably and at no profit during this pandemic."